Literature DB >> 32439497

Why do so many NASH trials fail?

Vlad Ratziu1, Scott L Friedman2.   

Abstract

Keywords:  Nonalcoholic steatohepatitis; clinical trial; fibrosis; steatosis

Year:  2020        PMID： 32439497     DOI： 10.1053/j.gastro.2020.05.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  20 in total

1.  Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease.

Authors:  Masato Yoneda; Takashi Kobayashi; Nogami Asako; Michihiro Iwaki; Satoru Saito; Atsushi Nakajima
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

2.  Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs.

Authors:  Valérie Duvivier; Stéphanie Creusot; Olivier Broux; Aurélie Helbert; Ludovic Lesage; Kevin Moreau; Nicolas Lesueur; Lindsay Gerard; Karine Lemaitre; Nicolas Provost; Edwige-Ludiwyne Hubert; Tania Baltauss; Angelique Brzustowski; Nathalie De Preville; Julia Geronimi; Lucie Adoux; Franck Letourneur; Adel Hammoutene; Dominique Valla; Valérie Paradis; Philippe Delerive
Journal:  J Clin Exp Hepatol       Date:  2021-09-08

Review 3.  Histological assessment based on liver biopsy: the value and challenges in NASH drug development.

Authors:  Xiao-Fei Tong; Qian-Yi Wang; Xin-Yan Zhao; Ya-Meng Sun; Xiao-Ning Wu; Li-Ling Yang; Zheng-Zhao Lu; Xiao-Juan Ou; Ji-Dong Jia; Hong You
Journal:  Acta Pharmacol Sin       Date:  2022-02-14       Impact factor: 7.169

Review 4.  Statins for treatment of chronic liver disease.

Authors:  Mohamad Kareem Marrache; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 3.287

Review 5.  Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.

Authors:  Don C Rockey; Scott L Friedman
Journal:  Gastroenterology       Date:  2021-01-30       Impact factor: 22.682

6.  Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.

Authors:  Wen-Yue Liu; Mohammed Eslam; Kenneth I Zheng; Hong-Lei Ma; Rafael S Rios; Min-Zhi Lv; Gang Li; Liang-Jie Tang; Pei-Wu Zhu; Xiao-Dong Wang; Christopher D Byrne; Giovanni Targher; Jacob George; Ming-Hua Zheng
Journal:  J Clin Transl Hepatol       Date:  2021-02-22

7.  Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.

Authors:  Santo Colosimo; Federico Ravaioli; Maria L Petroni; Lucia Brodosi; Francesca Marchignoli; Francesca A Barbanti; Anna S Sasdelli; Giulio Marchesini; Loris Pironi
Journal:  Liver Int       Date:  2021-02-10       Impact factor: 5.828

Review 8.  Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.

Authors:  Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan
Journal:  J Clin Transl Hepatol       Date:  2021-10-22

9.  Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.

Authors:  Dipankar Bhattacharya; Brittany Basta; Jose M Mato; Amanda Craig; David Fernández-Ramos; Fernando Lopitz-Otsoa; Darya Tsvirkun; Liat Hayardeny; Vasuretha Chandar; Robert E Schwartz; Augusto Villanueva; Scott L Friedman
Journal:  JHEP Rep       Date:  2021-01-28

Review 10.  Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective.

Authors:  Gwyneth Soon; Aileen Wee
Journal:  Clin Mol Hepatol       Date:  2020-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.